Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57.
Kreuzer
Karl-Anton
KA
le Coutre
Philipp
P
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D003582:Cytogenetics / Q000379:methods*; D018076:DNA, Complementary / Q000235:genetics; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012334:RNA, Neoplasm / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*
D000970:Antineoplastic Agents; D001549:Benzamides; D018076:DNA, Complementary; D010879:Piperazines; D011743:Pyrimidines; D012334:RNA, Neoplasm; D000068877:Imatinib Mesylate